Navigation Links
MiMedx Announces Launch of AmnioFix™ Nerve Wrap
Date:5/4/2011

MARIETTA, Ga., May 4, 2011 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane, announced today the launch of AmnioFix™ Nerve Wrap, the Company's latest biologic implant processed to offer surgical and healing options for nerve repair.

Produced from the MiMedx Group's proprietary Purion® process, AmnioFix™ Nerve Wrap is an allograft from amniotic tissue that is utilized for various nerve repair surgical procedures. Parker H. "Pete" Petit, Chairman and CEO, said, "AmnioFix™ Nerve Wrap is another minimally manipulated tissue offering created by our proprietary Purion® process that was developed by Surgical Biologics, a wholly-owned subsidiary of MiMedx that we acquired in  January 2011."

For use as an in vivo nerve wrap in peripheral nerve trauma, AmnioFix™ Nerve Wrap provides a protective barrier and contributes to the three phases of the natural healing process. . . inflammatory phase, proliferation phase and remodeling phase.

John Daniel, President and Founder of Surgical Biologics, stated "We are very excited to be pioneering another application for processed amniotic tissue. Ophthalmology was the industry's initial application for processed amniotic tissue. Surgical Biologics is the first and leading company specifically founded to promote the use of amniotic membrane in multiple surgical applications beyond ophthalmology. In addition to our new nerve wrap offering, Surgical Biologics has pioneered amniotic tissue uses in applications such as diabetic wound care, spinal surgery, orthopedics, burns, trauma and others."

Surgical Biologics has been supplying amniotic tissue for over five years with a stellar record of quality and safety. In addition to the MiMedx branded AmnioFix™ and EpiFix™ tissue, Surgical Biologics is also the leading supplier of amniotic tissue to distributors, having supplied over 30,000 implants to date. Included in the list of distributors to which Surgical Biologics supplies amniotic tissue are AFCell Medical, Alphatec Spine, BioArthro, NuShield, NuTech Medical, IOP Ophthalmics and Snoasis Medical.

Petit added, "Since its founding over five years ago, Surgical Biologics has made ground breaking advances in the use of amniotic membrane in new and innovative ways, and has clearly been the industry leader. The launch of AmnioFix™ Nerve Wrap is not only another example of their innovative approach; it is also an example of the caliber of new offerings that are resulting from the combination of Surgical Biologics with MiMedx."

About the Company

MiMedx is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants manufactured from human amniotic membrane. The Company has an experienced team poised to capitalize on its science and technology to generate rapid sales growth and profitability.  Our mantra is "Repair, don't replace" because our biochemists, engineers, designers and physicians believe it is better to augment repair when possible rather than replace traumatized, but otherwise healthy tissues and structures.  Our platform technologies, HydroFix™ and CollaFix™, and our newest platform technology, Purion® developed by our wholly-owned subsidiary, Surgical Biologics, have a vast number of potential applications in treating traumatized tissue and structures and MiMedx is focused on commercializing multiple applications for the Company's three technology platforms. In parallel, we are seeking strategic relationships, in selective categories, to more rapidly commercialize our technologies.  


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device
2. MiMedx Group Announces CE Mark for the HydroFix(TM) Spine Shield
3. MiMedx Group Announces Addition of Sales Director for Europe
4. MiMedx Group, Inc. Announces Release Date for Second Quarter Results
5. MiMedx Announces Agreement to Acquire Surgical Biologics
6. MiMedx Receives Additional CE Certification for Its HydroFix™ Technology
7. MiMedx Completes Acquisition of Surgical Biologics
8. MiMedx Group, Inc. Announces Release Date for First Quarter Results
9. MiMedx to Attend International Society for the Advancement of Spine Surgery Annual Meeting
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... and CEO, will be presenting at Source Capital Group,s 2016 ... NY at 2:15 p.m. ET on Wednesday, February ... Panel discussion taking place at 3:15 p.m. ET. ... one hour after the conclusion of the live event. The ...
(Date:2/5/2016)... , February 5, 2016 ... Market Research report states that the global active pharmaceuticals ... and is predicted to reach US$185.9 bn by 2020. ... 6.50% from 2014 to 2020. The title of the ... Captive/Contract Manufactured, by Geography, and by Therapeutic Area) - ...
(Date:2/5/2016)... , Feb. 5, 2016  Zimmer Biomet Holdings, Inc. ... the previously announced underwritten secondary offering of 11,027,558 shares ... consisting of affiliates of Blackstone and Goldman Sachs.  The ... initial price of $96.45 per share. The selling stockholders ...  Neither Zimmer Biomet nor any of its directors, officers ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... Francisco Canales, MD and Heather Furnas, ... Valley office. The technique utilizes the body’s own healing abilities to quickly rejuvenate ... are part of only a select few cosmetic surgeons bringing this procedure to ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active ... Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division ... completed his first three-year term as chief and began a second three-year term in ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... PROSHRED franchises from across the country gathered at the La Valencia Hotel in ... performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking away ...
(Date:2/5/2016)... ... 05, 2016 , ... Give To Cure today announced that it ... to Give To Cure’s campaign that is crowdfunding clinical trials to help find cures ... payments through a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
Breaking Medicine News(10 mins):